Vilay: Chronic Condition Management Platform for India

Chronic condition management in India is almost entirely relational and asynchronous. A patient with diabetes or hypertension visits a doctor, gets a prescription, and then disappears for three to six months until the next crisis or scheduled checkup.

Who does the work today:

• The patient's family manages medication schedules using phone alarms, paper calendars, or WhatsApp reminders set by the patient's children (typically working adults in metro or Gulf cities managing parents in tier-2/3 towns).
• The neighbourhood pharmacy acts as an informal coordinator. The pharmacist knows the patient's history, reminds them when refills are due, sometimes WhatsApp-photos the prescription to the doctor and collects the updated script without the patient travelling. This is especially common for hypertension and diabetes medications.
• The clinic receptionist maintains a handwritten or Excel log of follow-up dates, but this is rarely enforced. The doctor has no visibility into whether the patient is actually taking medications, eating correctly, or experiencing side effects between visits.
• Diagnostic chains (Apollo Diagnostics, Dr Lal PathLabs, SRL) handle report delivery via app or WhatsApp, but there is no systematic loop back to the prescribing doctor. The patient receives a PDF and either acts on it or doesn't.
• Corporate health coordinators (in companies with 200+ employees) use Excel sheets or simple Google Forms to track annual health check-up results, but this is episodic, not continuous condition management.

Where time and money leak:

• Patients travel to clinics for routine prescription renewals that could be handled digitally. A ₹200 auto-renewal consultation takes a half-day of travel and wages lost for a daily-wage worker.
• Doctors prescribe based on incomplete information. Medication doses are adjusted reactively during the next visit rather than proactively via a monitoring channel. This causes preventable complications that lead to hospitalisations.
• Families managing elderly parents in different cities have no secure, auditable channel to share symptom updates with the treating doctor. They rely on phone calls that the doctor cannot action.
• Pharmacies profit from repeat footfall but have no incentive to reduce it. Medication non-adherence means more frequent purchases, not less.
• Insurers (in corporate health plans) see high claim ratios from unmanaged chronic conditions but have no tools to intervene between policy and patient.

---

Who profits from it staying manual:

• Standalone diagnostic labs benefit from repeated tests ordered reactively rather than prevented proactively.
• Hospital networks that treat complications benefit from unmanaged chronic disease progressing to admission-ready stages.
• Unorganised neighbourhood pharmacies benefit from patients physically coming in for refills rather than ordering through a platform.
• Brokers who sell "health management" services to corporations at 30–40% margins, delivering little, benefit from opacity.

Who is hurt and would pay to change it:

• Pharma brands (Sanofi Diabetes, Sun Pharma, Cipla) have strong incentive to fund patient adherence programmes because medication non-adherence directly erodes their revenue. They already run disconnected call-centre-based adherence programmes at high cost with low fidelity. A digital channel that proves adherence data would be valuable to them for Rs.50–150 per patient per month.
• Corporate employers with group health insurance cover chronic disease employees. Their cost is not the insurance premium — it is absenteeism, presenteeism, and turnover from poorly managed conditions. A tool that demonstrably reduces diabetic or hypertensive complications in a 500-person workforce has clear ROI. Willingness to pay sits around Rs.100–200 per covered employee per month as a wellness add-on.
• Health insurers (Star Health, Care Health, HDFC Ergo group covers) would pay for anything that reduces claim frequency. India has 35–40 million people covered under group health policies where chronic disease is the primary cost driver.
• Doctors in solo or small-clinic practice are harmed by the current state but have the least power to change it. They lack staff to do follow-up calls. They would use a free or low-cost tool that reduces their phone-call burden.

Who would not pay:

• Individual patients from lower-middle class households are accustomed to free WhatsApp calls and resistant to subscription fees for health management. The willingness is there in intent but absent at point of payment.
• Government district hospitals have no budget line for SaaS tools of this nature.

---

Day one product: A WhatsApp-based bot that clinics activate for patients with confirmed hypertension or Type-2 diabetes at the point of prescription. The bot sends a weekly check-in: "How many days did you take your medication?" with a simple reply button. It also collects three data points — morning fasting blood sugar reading (for diabetics), any adverse symptoms from a short list, and a mood score. The clinic dashboard shows each patient's 4-week adherence trend.

What it does not do on day one: It does not book appointments, order medicines, or replace the doctor. It is a structured communication layer that makes the patient's post-visit state visible to the clinic.

Who pays:

• Clinic or doctor at a SHAPE of per patient per month: ₹200–350 per active chronic patient on the platform. A clinic with 200 chronic patients on board pays ₹4,000–7,000 per month. The value to the doctor is reduced phone-call volume (estimated 30–50% fewer "doctor, my sugar is 180, is this okay?" WhatsApp texts) and better data at the next consultation. This is a meaningful but not existential cost for a solo practitioner.
• Secondary revenue (later): Pharma brand sponsorship of the bot interface. Not day one, but within 6 months. The pharma company gets anonymised, aggregated adherence data for their molecule in a geography. This is a ₹80–120 per patient per month subsidy, reducing effective price to the clinic.

The narrowest version to test: A single-doctor endocrinology or general medicine clinic in Hyderabad or Pune, 30 patients onboarded, ₹250 per patient per month, WhatsApp-only, no app to download. If the doctor renews the subscription after month two, the wedge holds. If the doctor says "I never check it," the wedge fails.

---

Confirmed active Indian players:

• Practo offers appointment booking and teleconsultation but does not provide ongoing condition management between visits. Doctor engagement ends at consultation.
• 1mg handles pharmacy delivery, diagnostics, and some teleconsultation but has no persistent patient monitoring layer with clinic visibility.
• Medibuddy (now DenefITs) provides corporate health check-up management and some teleconsultation services for employer groups. Chronic condition tracking is not their primary function.
• MFine was active in teleconsultation and AI-assisted diagnostics but has had operational disruptions. Current status: unverified.
• Niramai focuses on breast cancer screening, not chronic disease management.
• Mfine — status uncertain; significant funding spent, unclear if platform is actively acquiring clinics.
• Siemens Healthineers and GE Healthcare have remote patient monitoring hardware but are enterprise hardware companies, not SaaS platforms for small clinics.
• Biofourmis (global, with India presence) does remote patient monitoring and has worked with pharma on patient adherence programmes. This is the closest to the wedge in concept, but targets hospital-grade monitoring and pharma clinical trials, not solo-clinic chronic disease management. Their pricing is enterprise-scale, not SMB.
• Healthplify is a chronic disease management platform with some India presence. Product scope appears broader than the wedge — more EMR-integrated than WhatsApp-first.

No credible Indian platform owns the "WhatsApp-first, solo clinic, per patient per month" positioning for chronic disease follow-up. This is not a validated gap — it may mean the wedge is empty or that the economics have never been tested at this scale.

---

Kill fact 1: Doctors will not engage with any digital follow-up channel, regardless of UX.

How to check cheaply: Call or visit 10 solo or two-doctor clinics in one city (targeting endocrinology, general medicine, and cardiology). Ask: "Do you currently have any way to know if your diabetes patient took their medication between visits? Would you pay ₹250 per patient per month for a weekly automated check-in?" Do not pitch the product. Just ask the problem. If 7 of 10 say they do not care or do not have bandwidth to act on any data, the wedge is dead. Budget: ₹0 if done by founder personally. ₹3,000–5,000 if done by a field research intern for travel costs. Pass mark: at least 5 of 10 express interest or confirm the problem is real.

Kill fact 2: Patients will not respond to a weekly WhatsApp check-in without a financial incentive or gamification that cannot be sustained.

How to check cheaply: Set up a two-week WhatsApp broadcast on a personal number to 20 patients you know (friends, family, acquaintances with chronic conditions). Send one message per week asking: "Did you take your blood pressure medication this week? Reply 1 for Yes, 2 for No." Track response rate. If response rate is below 40%, patients are not engaged enough to sustain the core loop. Budget: ₹0. Pass mark: 40% or higher response rate without any incentive offered.

Kill fact 3: The unit economics do not work at clinic scale — acquisition cost per clinic exceeds 18-month LTV.

How to check cheaply: Calculate the fully loaded cost to sign up and onboard one clinic (founder time, travel, WhatsApp Business API costs, dashboard hosting per patient at scale). If the cost exceeds ₹5,000 per clinic and the clinic pays ₹250 per patient per month with an average of 50 patients, the payback period is 4 months. If average patient count is 15, payback is 13 months — which may be too long for a small team to survive. Build a simple model using actual API pricing from Twilio or Gupshup, plus estimated onboarding hours. Pass mark: under 6-month payback on average clinic with 30+ chronic patients.

---

Month 1 — Problem validation (budget: ₹5,000)

• Founder visits 20 solo or small-clinic practices in Pune and Hyderabad. 10 endocrinology or internal medicine, 10 general medicine or cardiology. No product demo — just structured problem interviews using the script above. Every conversation logged in a simple spreadsheet with columns: city, specialty, number of chronic patients seen per week, current follow-up method, stated pain point (1–5), willingness to pay (yes/no/maybe with price range).
• Output: 20 logged interviews, a synthesised pain point score, and a list of the 5 clinics that said yes most enthusiastically.

Month 2 — MVP and pilot setup (budget: ₹25,000)

• Build a WhatsApp Business bot using Gupshup or Twilio. Minimum viable version: weekly broadcast to patient list, simple reply parsing, manual dashboard showing patient responses per clinic. Do not build an app. Cost: developer 5–8 days at freelance rates (₹15,000–20,000) or founder builds with Bubble or no-code.
• Onboard the 5 most enthusiastic clinics from Month 1. Target: 20–30 patients per clinic, all hypertension or Type-2 diabetes, all previously known to the clinic (no cold acquisition). No payment charged in month 2 — free trial in exchange for feedback.
• Weekly standup with each clinic: 15-minute call to review dashboard together and note what data they would act on.

Month 3 — First revenue and churn signal (budget: ₹10,000)

• Convert 3 of 5 clinics to paid at ₹250 per patient per month. This requires the clinics to actually collect from patients or pay from their own pocket. Test both models: clinic pays directly vs. patients pay a ₹30–50 per month add-on to their visit fee.
• Track: response rate to weekly check-in (target 50%+), clinic dashboard review frequency, whether doctor acted on any data (prescription change, flagged patient called in), and whether clinic renews after month 3.
• Second cohort: add 5 new clinics without a free trial. Charge from day one at ₹200 per patient per month. This tests whether the product has value before trust is built.

Pass mark to continue: After 90 days — at least 3 of 5 original clinics on paid subscription, at least 60% patient response rate to weekly message, at least one instance of a doctor changing a prescription based on dashboard data. If these three conditions are met, the wedge is live enough to invest in a proper product build. If not, iterate on the product hypothesis before building anything durable.

---

AGENCIFY first, PRODUCTIZE second, AI-FY never as the core offer.

The chronic condition management gap in India is not a product gap — it is a coordination gap that requires human effort to bootstrap. The first move must be a service layer (someone manually driving adoption at the clinic level, onboarding patients, and demonstrating value to the doctor) because a SaaS dashboard with zero clinic engagement will rot. Once a repeatable onboarding playbook exists and the per-clinic LTV is validated, productize the manual coordination into software. AI-fy the data interpretation layer only after the software has enough patient data to make the AI meaningful — using AI before there is data is not AI-fy, it is fiction. The real business here is the clinic relationship and the patient adherence data, in that order; the software is the vehicle, not the asset.

Availability confirmed against the .in registry (RDAP) on 2026-09-21. Prices and ownership read from our own intelligence tables. Nothing here is estimated.

Single-word, available now

• vilay.in — available
• vilays.in — available
• coulds.in — available
• vilaies.in — available
• vilay.co.in — available
• vilaies.com — available
• vilays.co.in — available
• coulds.co.in — available
• vilaies.co.in — available

Also available (compound)

• vilayhub.in
• vilaymart.in
• vilaykart.in
• vilaymandi.in
• vilaybazaar.in

Listed for sale

• vilay.com · price not listed on afternic · seller holds 21344 domains

In the expiry pipeline — watch

• could.co.in · 414 days · score 65

Taken and developed — do not chase

• chronic.in · entropy 4.70

---

Generated 2026-09-21 20:40 UTC. Topic from our research queue; no market-size figure appears here unless a source is named. The domain block above is read from our own intelligence tables and confirmed at the .in registry (RDAP); the model wrote the analysis, not the domain facts.